At Thermo Fisher Scientific, we have developed advanced next-generation sequencing solutions to address key challenges in the molecular analysis of hematologic malignancies.
Watch our virtual symposium on demand to learn how we can help simplify your path to answers in the study of myeloid and lymphoid cancer.
Presenter: Marianne Grantham
Head of Cytogenetics and Molecular Haematology,
Barts Health NHS Trust, UK
Presenter: Dr. Dolors Colomer
Head of Hematopathology
Hospital Clinic, IDIBAPS, University of Barcelona, Spain
Presenters: Dr Lihui Wang, Molecular Lead, HODS
Dr. Geetha Menon Clinical Director, HODS
Cheshire & Merseyside Cancer Network, Liverpool, UK
The first myeloid genomic profiling solution that can deliver an NGS report, covering all key DNA and RNA targets, in as little as one day on the Ion Torrent Genexus System.
Advanced NGS solutions that can sequence multiple B- and T-cell receptor targets in a single reaction for highly sensitive and specific clone detection.
Dr. Diana Morlote
University of Alabama at Birmingham
During this presentation, Dr. Diana Morlote, assistant professor of pathology at the University of Alabama at Birmingham, will discuss the recent implementation of a rapid, automated next-generation sequencing (NGS) assay in her research laboratory for genomic profiling of Acute Myeloid Leukemia (AML) and other related hematological disorders. The data collected from several cases using the Oncomine Myeloid Assay GX v2 by Thermo Fisher Scientific will be presented. Analytical performance will be discussed for various key mutations detected using DNA inputs. Morlote will describe how this solution addresses key challenges with molecular analysis of AML and other related malignancies. This research furthers our understanding of malignant hematological disorders and may lead to better care in the future.
For Research Use Only. Not for use in diagnostic procedures.